3B BlackBio Dx Ltd: PCR Profits, Agro Side Hustle, and a Belgian Detour
Date of Publishing -
Spotted a factual error — a wrong number, date, or fact? Tell us and we will check the source.
1. At a Glance
Once known as Kilpest India, now rebranded with a cool biotech name, 3B BlackBio Dx Ltd is the small-cap desi diagnostic player punching above its weight. At ₹1,498/share (market cap ~₹1,286 Cr), it’s making ~₹99 Cr sales with ~50% OPM. That’s not a typo—half the revenue turns into operating profit. While biggies like Dr. Lal PathLabs sell your blood reports, 3B sells the kits those labs use. Throw in an agro-chemical side hustle and now a Belgian acquisition, and you’ve got a biotech soap opera.
2. Introduction
Founded in 2011 but really emerging post-COVID testing frenzy, 3B BlackBio Dx is like that nerd who suddenly got popular after inventing a new phone app. They manufacture PCR-based diagnostic kits (the same PCR test that ruined weddings during lockdowns), NGS kits, enzymes, and rapid antigen tests under the TRUPCR, TRUNGS, and TRURAPID brands.
But here’s the twist—they’re also selling larvicides and fertilizers through government tenders. That’s right, one division helps detect cancer mutations, the other kills mosquitoes in your gali.
FY23 revenue split: Diagnostics ~81%, Agrochemicals ~19%. And exports are rising: TRUPCR assays already sold in 40+ countries, plus a UK-based subsidiary to handle Europe. In FY25, they announced buying Belgium’s Coris Holding SRL (₹58 Cr revenue, antimicrobial diagnostics). A gutsy international expansion for a company with less sales than a single metro mall.
Question: Would you trust a company making both cancer kits and mosquito repellents? Or is diversification the new jugaad?
3. Business Model (WTF Do They Even Do?)
Think of 3B BlackBio as two cousins running one shop:
Low-margin, but steady orders (ex: ₹1.59 Cr larvicide export in Jan 2024).
Their moat is branding (“TRUPCR” is well known among labs) + regulatory certifications. Bonus: almost debt-free, meaning profits don’t vanish into bank EMIs.
